X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with Ingersoll Rand - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs INGERSOLL RAND - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

INGERSOLL RAND 
   Change

Ingersoll Rand is a global diversified industrial company, engaged in the business of providing solutions for infrastructure development, industrial solutions, residential solutions and security technologies. Ingersoll-Rand manufactures a wide range ... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES INGERSOLL RAND INDOCO REMEDIES/
INGERSOLL RAND
 
P/E (TTM) x 43.6 19.4 225.4% View Chart
P/BV x 2.8 1.6 170.2% View Chart
Dividend Yield % 0.8 1.1 74.5%  

Financials

 INDOCO REMEDIES   INGERSOLL RAND
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
INGERSOLL RAND
Mar-17
INDOCO REMEDIES/
INGERSOLL RAND
5-Yr Chart
Click to enlarge
High Rs360789 45.7%   
Low Rs249625 39.9%   
Sales per share (Unadj.) Rs119.0214.5 55.5%  
Earnings per share (Unadj.) Rs8.424.5 34.2%  
Cash flow per share (Unadj.) Rs15.228.2 54.0%  
Dividends per share (Unadj.) Rs1.606.00 26.7%  
Dividend yield (eoy) %0.50.8 61.9%  
Book value per share (Unadj.) Rs70.7336.3 21.0%  
Shares outstanding (eoy) m92.1531.57 291.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.63.3 77.7%   
Avg P/E ratio x36.428.9 126.2%  
P/CF ratio (eoy) x20.025.1 79.9%  
Price / Book Value ratio x4.32.1 205.0%  
Dividend payout %19.124.5 78.0%   
Avg Mkt Cap Rs m28,08322,315 125.8%   
No. of employees `0006.00.7 877.3%   
Total wages/salary Rs m2,167937 231.1%   
Avg. sales/employee Rs Th1,817.09,842.7 18.5%   
Avg. wages/employee Rs Th359.01,362.5 26.3%   
Avg. net profit/employee Rs Th127.71,123.2 11.4%   
INCOME DATA
Net Sales Rs m10,9686,772 162.0%  
Other income Rs m40588 6.8%   
Total revenues Rs m11,0077,360 149.6%   
Gross profit Rs m1,565682 229.4%  
Depreciation Rs m633118 536.3%   
Interest Rs m628 786.1%   
Profit before tax Rs m9091,144 79.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m139371 37.4%   
Profit after tax Rs m771773 99.7%  
Gross profit margin %14.310.1 141.6%  
Effective tax rate %15.332.4 47.0%   
Net profit margin %7.011.4 61.6%  
BALANCE SHEET DATA
Current assets Rs m5,7259,125 62.7%   
Current liabilities Rs m5,4541,346 405.2%   
Net working cap to sales %2.5114.9 2.1%  
Current ratio x1.06.8 15.5%  
Inventory Days Days6247 132.1%  
Debtors Days Days7250 142.4%  
Net fixed assets Rs m5,3071,280 414.5%   
Share capital Rs m184316 58.4%   
"Free" reserves Rs m6,33110,300 61.5%   
Net worth Rs m6,51610,616 61.4%   
Long term debt Rs m1,3230-   
Total assets Rs m11,97012,057 99.3%  
Interest coverage x15.6145.8 10.7%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.90.6 163.1%   
Return on assets %7.06.5 107.5%  
Return on equity %11.87.3 162.5%  
Return on capital %12.410.9 114.2%  
Exports to sales %026.5 0.0%   
Imports to sales %020.1 0.0%   
Exports (fob) Rs mNA1,792 0.0%   
Imports (cif) Rs mNA1,363 0.0%   
Fx inflow Rs m4,5071,792 251.5%   
Fx outflow Rs m1,1411,603 71.2%   
Net fx Rs m3,366188 1,787.0%   
CASH FLOW
From Operations Rs m8861,215 73.0%  
From Investments Rs m-1,7061,407 -121.2%  
From Financial Activity Rs m1,316-231 -569.8%  
Net Cashflow Rs m4972,391 20.8%  

Share Holding

Indian Promoters % 59.2 0.0 -  
Foreign collaborators % 0.0 74.0 -  
Indian inst/Mut Fund % 12.5 7.2 173.6%  
FIIs % 6.0 0.5 1,200.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 18.3 122.4%  
Shareholders   12,805 19,522 65.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   COX & KINGS  JSW HOLDINGS  RELIGARE ENT.  BAJAJ FINANCE  IIFL HOLDINGS  



Today's Market

Sensex Trades on a Volatile Note; FMCG, Pharma Stocks Rally(12:30 pm)

After opening the day flat share markets in India are trading on a dull note and are presently trading marginally above the dotted line.

Related Views on News

INDOCO REMEDIES Announces Quarterly Results (4QFY18); Net Profit Up 14.3%

Jun 19, 2018 | Updated on Jun 19, 2018

For the quarter ended March 2018, INDOCO REMEDIES has posted a net profit of Rs 205 m (up 14.3% YoY). Sales on the other hand came in at Rs 3 bn (down 2.6% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Jun 22, 2018 02:43 PM

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 5-YR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS